BCL2 and gastric cancer: It was shown to be downregulated and might function as a tumor suppressor by targeting Myc [35], FSCN1 [36] in gastric cancer, ZEB1 [37] in oral squamous cell carcinoma, CRKL [38] in hepatocellular carcinoma, TLN1 [39] in nasopharyngeal carcinoma, AKT1 in melanoma [40], or BCL2 and SP1 in esophageal carcinomas [41].